Core Insights - Summit Therapeutics Inc. is advancing the development of ivonescimab for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) through multiregional Phase III clinical trials [1][2] Company Developments - The company has partnered with GORTEC to activate clinical sites for a Phase III study evaluating ivonescimab monotherapy and its combination with ligufalimab [2] - The US FDA has accepted the Biologics License Application (BLA) for ivonescimab in combination with chemotherapy [3] - Summit has also partnered with GSK plc to assess ivonescimab in combination with B7-H3 and risvutatug rezetecan across multiple solid tumors [3] Financial Performance - As of the end of Q4 2025, the company reported $713.4 million in cash and cash equivalents and $412.3 million in short-term investments [4] - The net loss for the full year 2025 increased to $347.2 million, or $0.46 per share, compared to a loss of $179.3 million, or $0.24 per share, in 2024 [4] Company Overview - Summit Therapeutics is a Miami-based biopharmaceutical company focused on oncology therapies aimed at improving patient quality of life and addressing unmet medical needs, with ivonescimab as its lead candidate targeting PD-1 and VEGF for solid tumors [5]

Core Viewpoint - Akeso, Inc. has initiated a pivotal Phase III clinical trial for ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, aimed at treating metastatic pancreatic cancer in combination with chemotherapy and potentially ligufalimab [1][3] Industry Overview - Pancreatic cancer is a highly aggressive malignancy with a rising global incidence, leading to approximately 511,000 new cases and 467,000 deaths in 2022. The overall survival rate remains alarmingly low, with current first-line treatments primarily consisting of chemotherapy showing limited success, resulting in a median overall survival of less than one year [4] - The unique immune evasion mechanisms and immunosuppressive tumor microenvironment of pancreatic cancer have made it resistant to existing therapies, with no immunotherapy approved for first-line treatment to date [2][4] Company Overview - Akeso is a leading biopharmaceutical company focused on developing innovative biological medicines, with a robust pipeline of over 50 assets in various therapeutic areas, including cancer. The company employs an integrated R&D innovation system and has developed a comprehensive drug development platform [10] - The ongoing Phase III trial for ivonescimab is part of Akeso's strategy to address significant unmet clinical needs in oncology, particularly for metastatic pancreatic cancer [3][10]